Trial Profile

A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BNC 210 (Primary)
Indications Social phobia
Focus Therapeutic Use
Acronyms PREVAIL
Sponsors Bionomics

Most Recent Events

18 Mar 2025 Results assessing efficacy and safety of BNC210, published in the Psychiatry Research.
06 Dec 2023 According to a Bionomics Limited media release, data from this study were presented at the 2023 American College of Neuropsychopharmacology Annual Meeting.
06 Dec 2023 Results presented in a Bionomics Limited media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com